Zheni Stavre1,2, Katherine Upchurch1,2, Jonathan Kay1,2, Ellen M Gravallese3,4. 1. Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, 55 Lake Ave North, Worcester, MA, 01655, USA. 2. University of Massachusetts Medical School, Lazar Research Building, 364 Plantation Street, Worcester, MA, 01605, USA. 3. Department of Medicine, Division of Rheumatology, UMass Memorial Medical Center, 55 Lake Ave North, Worcester, MA, 01655, USA. ellen.gravallese@umassmed.edu. 4. University of Massachusetts Medical School, Lazar Research Building, 364 Plantation Street, Worcester, MA, 01605, USA. ellen.gravallese@umassmed.edu.
Abstract
PURPOSE OF REVIEW: We review the pathways, cytokines, and concepts important to the pathogenesis of bone resorption and formation in rheumatoid arthritis (RA) and spondyloarthritis (SpA). RECENT FINDINGS: Research in bone biology has shed light on the pathogenesis of the joint destruction that occurs in RA and in peripheral SpA. However, understanding the mechanisms behind the bone formation seen in peripheral and axial SpA has been challenging. Mouse models have been used to gain an understanding of key signaling pathways, cytokines and cells regulating inflammation in these diseases. Biologic therapies directed against these targets have been developed to control both inflammation and effects on bone. Although biologic therapies improve joint inflammation in both RA and SpA, leading to a decrease in pain and improving quality of life for patients, the long-term effects of such therapies must also be evaluated by assessing their impact on structural progression. Inhibition of radiographic progression in both RA and peripheral SpA has been easier to demonstrate than in axial SpA. Here, we discuss the similarities and differences among biologic therapies as they pertain to radiographic progression.
PURPOSE OF REVIEW: We review the pathways, cytokines, and concepts important to the pathogenesis of bone resorption and formation in rheumatoid arthritis (RA) and spondyloarthritis (SpA). RECENT FINDINGS: Research in bone biology has shed light on the pathogenesis of the joint destruction that occurs in RA and in peripheral SpA. However, understanding the mechanisms behind the bone formation seen in peripheral and axial SpA has been challenging. Mouse models have been used to gain an understanding of key signaling pathways, cytokines and cells regulating inflammation in these diseases. Biologic therapies directed against these targets have been developed to control both inflammation and effects on bone. Although biologic therapies improve joint inflammation in both RA and SpA, leading to a decrease in pain and improving quality of life for patients, the long-term effects of such therapies must also be evaluated by assessing their impact on structural progression. Inhibition of radiographic progression in both RA and peripheral SpA has been easier to demonstrate than in axial SpA. Here, we discuss the similarities and differences among biologic therapies as they pertain to radiographic progression.
Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Nicole C Walsh; Susan Reinwald; Catherine A Manning; Keith W Condon; Ken Iwata; David B Burr; Ellen M Gravallese Journal: J Bone Miner Res Date: 2009-09 Impact factor: 6.741
Authors: Craig A Murphy; Claire L Langrish; Yi Chen; Wendy Blumenschein; Terrill McClanahan; Robert A Kastelein; Jonathon D Sedgwick; Daniel J Cua Journal: J Exp Med Date: 2003-12-08 Impact factor: 14.307
Authors: Christian S Thudium; Signe Holm Nielsen; Samra Sardar; Ali Mobasheri; Willem Evert van Spil; Rik Lories; Kim Henriksen; Anne-Christine Bay-Jensen; Morten A Karsdal Journal: BMC Musculoskelet Disord Date: 2020-11-28 Impact factor: 2.362